Every Brain-Computer Interface Company in 2026: The Complete List
The definitive directory of every brain-computer interface company operating globally in 2026. From invasive neural implants to non-invasive EEG headsets, this list covers 43 companies across 13 countries building the future of human-machine communication. Each entry links to a full company profile with funding history, clinical trial data, product specifications, and recent news.
| Company | Focus | Founded | HQ | CEO | Funding | Headcount | Status |
|---|---|---|---|---|---|---|---|
| Neuralink Corp | Invasive | 2016 | $1.29B | ~400 | active | ||
| Synchron | Invasive | 2016 | $365M+ | ~100 | active | ||
| Precision Neuroscience | Invasive | 2021 | $183M | ~117 | active | ||
| Blackrock Neurotech | Invasive | 2008 | $250M+ | ~166 | active | ||
| Paradromics | Invasive | 2015 | $127M | ~98 | active | ||
| BrainGate Consortium | research | 2004 | — | — | active | ||
| Science Corporation | Invasive | 2021 | $490M | ~120 | active | ||
| Merge Labs | Non-Invasive | 2025 | $252M | ~30 | active | ||
| EMOTIV | consumer | 2011 | $12M | ~93 | active | ||
| OpenBCI | research | 2014 | $2M+ | ~23 | active | ||
| Neurable | consumer | 2015 | $65M | ~40 | active | ||
| Cognixion | Non-Invasive | 2014 | $29M | ~32 | active | ||
| Kernel | Non-Invasive | 2016 | $161M | ~60 | active | ||
| NeuroPace | Invasive | 1997 | $250M+ | ~200 | active | ||
| MindMaze | Non-Invasive | 2012 | $348M | ~118 | active | ||
| ONWARD Medical | Invasive | 2014 | CHF 100M+ | ~100 | active | ||
| INBRAIN Neuroelectronics | Invasive | 2019 | $60M+ | ~80 | active | ||
| Medtronic Neuromodulation | DBS | 1949 | Public (NYSE: MDT) | 90,000+ (company-wide) | active | ||
| Abbott Neuromodulation | DBS | 2017 | Public (NYSE: ABT) | 113,000+ (company-wide) | active | ||
| Boston Scientific Neuromodulation | DBS | 1979 | Public (NYSE: BSX) | 45,000+ (company-wide) | active | ||
| Nalu Medical | DBS | 2014 | $446M | ~200 | acquired | ||
| Saluda Medical | DBS | 2011 | $668M | ~483 | active | ||
| Motif Neurotech | Invasive | 2022 | $30M+ | ~25 | active | ||
| Subsense | Non-Invasive | 2024 | $27M | ~15 | stealth | ||
| CereGate | DBS | 2019 | $15M+ (estimated) | ~30 | active | ||
| Neurolutions | Non-Invasive | 2011 | — | ~40 | acquired | ||
| CTRL-labs | Non-Invasive | 2015 | — | — | acquired | ||
| Gestala | Non-Invasive | 2024 | $21.6M | ~20 | active | ||
| Neuracle Medical Technology | Invasive | 2011 | Undisclosed | ~100 | active | ||
| g.tec medical engineering | research | 1999 | — | ~100 | active | ||
| ANT Neuro | research | 1997 | $16.6M revenue | ~60 | active | ||
| Compumedics | research | 1987 | Public (ASX: CMP) | ~200 | active | ||
| Wearable Sensing | research | 2013 | — | ~15 | active | ||
| mBrainTrain | research | 2012 | — | ~15 | active | ||
| Bitbrain | research | 2010 | — | ~40 | active | ||
| BrainCo | Non-Invasive | 2015 | $370M | ~200 | active | ||
| NeuroSky | consumer | 2004 | $30M+ | ~60 | active | ||
| BrainRobotics | Non-Invasive | 2015 | — | — | active | ||
| MELTIN MMI | Non-Invasive | 2013 | $20M | ~30 | active | ||
| BrainAccess (Neurotechnology) | research | 2019 | — | ~30 | active | ||
| Idun Technologies | consumer | 2017 | CHF 12M | ~12 | active | ||
| InteraXon (Muse) | consumer | 2007 | $41M | ~62 | active | ||
| BCI2000 | research | 2000 | — | — | active |
The brain-computer interface industry in 2026 consists of 43 companies across 13 countries, spanning invasive implants, non-invasive wearables, neuromodulation devices, and software platforms. The sector is dominated by a handful of well-funded Tier 1 players — Neuralink ($1.29B raised), Synchron ($365M+), Blackrock Neurotech ($250M+), and Precision Neuroscience ($183M) — that have achieved human clinical milestones.
The competitive landscape is bifurcating: invasive BCIs led by Neuralink and Synchron target high-bandwidth medical restoration, while non-invasive companies like Kernel, Emotiv, and Neurable pursue consumer and enterprise use cases with lower regulatory barriers. Regulatory progress is accelerating, with multiple companies holding FDA Breakthrough Device Designation and 510(k) clearances.
For investors, researchers, and industry analysts, this directory provides a comprehensive reference point. Every company name links to a detailed profile page with funding history, product specifications, clinical data, and latest news.